Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2019 08:00 ET | Source: Ceapro Inc.

Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids

EDMONTON, Alberta, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
November 13, 2019 09:00 ET | Source: Ceapro Inc.

Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights

- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery systems - - Third...
October 29, 2019 08:05 ET | Source: Ceapro Inc.

Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides

EDMONTON, Alberta, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
October 16, 2019 07:00 ET | Source: Ceapro Inc.

Ceapro Begins Trading on the OTCQX Best Market

EDMONTON, Alberta, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
September 25, 2019 08:30 ET | Source: Ceapro Inc.

Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research

EDMONTON, Alberta, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
September 10, 2019 08:00 ET | Source: Ceapro Inc.

Ceapro Inc. to Present at the Fall Investor Summit in New York

EDMONTON, Alberta, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
August 28, 2019 09:00 ET | Source: Ceapro Inc.

Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights

- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development of delivery systems - ...
August 27, 2019 08:45 ET | Source: Ceapro Inc.

Ceapro Announces Research Funding Award from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada for Joint Projects with McMaster University

- Collaboration to develop innovative drug delivery systems using disruptive PGX Technology to optimize drug formulations used in areas of high unmet medical needs such as idiopathic lung fibrosis and...
August 15, 2019 09:00 ET | Source: Ceapro Inc.

Ceapro Inc. Announces Signing of a Contribution Agreement with National Research Council of Canada

EDMONTON, Alberta, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
June 10, 2019 16:05 ET | Source: Ceapro Inc.

Ceapro Announces Results of 2019 Shareholders’ Meeting

EDMONTON, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...